{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:43:57Z","timestamp":1789839837393,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.contraception.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:34:00Z","timestamp":1582252440000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0\u00a0mg over 6 cycles in female adolescents, with a 7-cycle extension phase"],"prefix":"10.1016","volume":"101","author":[{"given":"Dan","family":"Apter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.02.004_b0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/2042098614548857","article-title":"Combined oral contraceptives: prescribing patterns, compliance, and benefits versus risks","volume":"5","author":"Brynhildsen","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.contraception.2020.02.004_b0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/WHE.10.36","article-title":"Estrogen-free oral hormonal contraception: benefits of the progestin-only pill","volume":"6","author":"de Melo","year":"2010","journal-title":"Womens Health (Lond)."},{"key":"10.1016\/j.contraception.2020.02.004_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous embolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.contraception.2020.02.004_b0020","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis","volume":"25","author":"Glisic","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.contraception.2020.02.004_b0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/13625189809167250","article-title":"A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 \u03bcg\/day or levonorgestrel 30\u03bcg\/day","volume":"3","author":"Korver","year":"1998","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.02.004_b0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","article-title":"Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability","volume":"92","author":"Archer","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.02.004_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.contraception.2004.07.016","article-title":"Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake","volume":"71","author":"Korver","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.02.004_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.contraception.2015.12.007","article-title":"Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake","volume":"93","author":"Duijkers","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.02.004_b0045","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1089\/jwh.2010.1963","article-title":"Studying the use of oral contraception: a review of measurement approaches","volume":"19","author":"Hall","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.contraception.2020.02.004_b0050","unstructured":"American College of Obstetricians and Gynecologists. Progestin-Only Hormonal Birth Control: Pill and Injection. https:\/\/www.acog.org\/Patients\/FAQs\/Progestin-Only-Hormonal-Birth-Control-Pill-and-Injection?IsMobileSet=false. FAQ186, March 2018. Accessed November 27, 2019."},{"key":"10.1016\/j.contraception.2020.02.004_b0055","unstructured":"Centers for Disease Control and Prevention. Reproductive Health: Contraception. https:\/\/www.cdc.gov\/reproductivehealth\/contraception\/index.htm. Accessed November 27, 2019."},{"key":"10.1016\/j.contraception.2020.02.004_b0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/13625187.2015.1044082","article-title":"A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24\/4 regimen","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.02.004_b0065","unstructured":"Kubba A et al. A pivotal, multicenter, double-blind, double-dummy, randomized trial on the contraceptive efficacy, tolerability and safety of a novel oestrogen free contraceptive (Drospirenone 4 mg 24+4) over 9 cycles in comparison with Desogestrel 75 \u03bcg. Eur J Contracept Reprod Health Care 2018; 23, Suppl."},{"key":"10.1016\/j.contraception.2020.02.004_b0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/13625187.2017.1295437","article-title":"Missed pills: frequency, reasons, consequences and solutions","volume":"22","author":"Chabbert-Buffet","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.02.004_b0075","first-page":"670","article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","volume":"15","author":"Lortscher","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.contraception.2020.02.004_b0080","first-page":"213","article-title":"Efficacy and safety of combined ethinyl estradiol\/drospirenone oral contraceptives in the treatment of acne","volume":"1","author":"Tan","year":"2010","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.contraception.2020.02.004_b0085","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.contraception.2020.02.004_b0090","series-title":"Beyond birth control: the overlooked benefits of oral contraceptive pills","author":"Jones","year":"2011"},{"issue":"2","key":"10.1016\/j.contraception.2020.02.004_b0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1471-0528.2009.02407.x","article-title":"The menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population based study of Australian teenagers","volume":"117","author":"Parker","year":"2010","journal-title":"BJOG"},{"issue":"6","key":"10.1016\/j.contraception.2020.02.004_b0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0002-9378(82)90433-1","article-title":"An epidemiologic study of young women with dysmenorrhea","volume":"144","author":"Andersch","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2020.02.004_b0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1054-139X(98)00147-5","article-title":"Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment","volume":"25","author":"Hillen","year":"1999","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.contraception.2020.02.004_b0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1542\/peds.2014-1511","article-title":"Hormonal contraceptive agents: a need for pediatric-specific studies","volume":"135","author":"Bonny","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.contraception.2020.02.004_b0115","first-page":"43","article-title":"Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates","volume":"7","author":"Villavicencio","year":"2016","journal-title":"Open Access J Contracept"},{"key":"10.1016\/j.contraception.2020.02.004_b0120","unstructured":"Internal data on file. CF111\/302 trial: A Pivotal, Multicenter, Double-Blind, Double Dummy, Randomised Trial on the Contraceptive Efficacy, Tolerability and Safety of LF111 (Drospirenone) Over 9 Cycles in Comparison with Desogestrel 0.075 mg. Clinical Trial Report, Final Version 1.0, 10 July 2014."},{"issue":"12","key":"10.1016\/j.contraception.2020.02.004_b0125","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/aogs.13688","article-title":"Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill","volume":"98","author":"Palacios","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2020.02.004_b0130","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global BMI Mortality Collaboration","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2020.02.004_b0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.publhealth.26.021304.144628","article-title":"Economic causes and consequences of obesity","volume":"26","author":"Finkelstein","year":"2005","journal-title":"Annu Rev Public Health"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420300573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420300573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:16:15Z","timestamp":1757880975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782420300573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0010782420300573"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.02.004","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0\u00a0mg over 6 cycles in female adolescents, with a 7-cycle extension phase","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}